MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$2,608K
Free Cash flow
-$2,133K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Net income (loss)
Stock-based compensation expense
Provision for inventory
Others
Negative Cash Flow Breakdown
Inventories
Accounts receivable
Purchases of property and equipm...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss)
3,309
-5,056
292
-2,329
Depreciation
1,505
1,407
1,318
1,391
Amortization of acquisition related intangible assets
0
0
0
12
Non-cash operating lease cost
465
464
499
495
(gain) loss on sale of assets
-
-
166
-
Loss on impairment of long-lived assets
-
-
0
0
Stock-based compensation expense
1,833
6,641
2,458
2,215
Deferred income taxes
129
108
-25
3
Provision for credit losses
-73
-24
56
76
Provision for inventory
1,543
1,032
852
1,127
Interest income on notes receivable
175
179
472
79
Gain on sale of assets
32
-904
-
451
Accounts receivable
3,228
2,180
1,545
-1,294
Inventories
6,013
5,407
1,779
443
Prepaid expenses, other current and long-term assets
-897
1,728
-1,311
-219
Accounts payable
-575
745
877
231
Operating lease liabilities
-469
-468
-471
-480
Accrued expenses, other current and long-term liabilities
265
-1,339
141
3,610
Income taxes
-65
1,190
335
-21
Net cash used in operating activities
-684
-4,846
4,637
6,870
Proceeds from sale of parcus medical, net
0
0
0
0
Proceeds from sale of intangible assets
0
-
0
0
Notes receivable
169
192
846
155
Purchases of property and equipment
1,449
1,431
648
1,887
Acquisition of intangible asset
-
-
0
0
Net cash used in by investing activities
-1,280
-1,239
198
-1,732
Proceeds from employee stock purchase program
198
-
239
0
Cash paid for tax withheld on vested restricted stock awards
58
1,657
4
13
Proceeds from exercises of equity awards
12
-
0
0
Repurchases of common stock
853
8,690
5,514
0
Net cash used in financing activities
-701
-10,347
-5,279
-13
Exchange rate impact on cash
57
-29
-65
-302
Decrease in cash and cash equivalents
-2,608
-16,461
-509
4,823
Cash and cash equivalents at beginning of period
41,020
57,481
57,990
57,159
Cash and cash equivalents at end of period
38,412
41,020
57,481
57,990
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Exchange rate impact on
cash
$57K
(-87.42%↓ Y/Y)
Decrease in cash and cash
equivalents
-$2,608K
(34.67%↑ Y/Y)
Canceled cashflow
$57K
Notes receivable
$169K
(-48.48%↓ Y/Y)
Proceeds from employee
stock purchase...
$198K
(-24.14%↓ Y/Y)
Proceeds from exercises
of equity awards
$12K
Net income (loss)
$3,309K
(137.42%↑ Y/Y)
Stock-based compensation
expense
$1,833K
(-66.12%↓ Y/Y)
Provision for inventory
$1,543K
(-59.84%↓ Y/Y)
Depreciation
$1,505K
(-43.48%↓ Y/Y)
Prepaid expenses, other
current and long-term...
-$897K
(-12.55%↓ Y/Y)
Non-cash operating lease
cost
$465K
(-56.42%↓ Y/Y)
Accrued expenses, other
current and long-term...
$265K
(105.05%↑ Y/Y)
Deferred income taxes
$129K
(760.00%↑ Y/Y)
Net cash used in by
investing activities
-$1,280K
(-212.97%↓ Y/Y)
Net cash used in
financing activities
-$701K
(86.67%↑ Y/Y)
Net cash used in
operating activities
-$684K
(-114.42%↓ Y/Y)
Canceled cashflow
$169K
Canceled cashflow
$210K
Canceled cashflow
$9,946K
Purchases of property and
equipment
$1,449K
(-66.23%↓ Y/Y)
Repurchases of common stock
$853K
(-78.52%↓ Y/Y)
Inventories
$6,013K
(367.01%↑ Y/Y)
Cash paid for tax
withheld on vested...
$58K
(-96.26%↓ Y/Y)
Accounts receivable
$3,228K
(589.83%↑ Y/Y)
Accounts payable
-$575K
(46.06%↑ Y/Y)
Operating lease
liabilities
-$469K
(55.12%↑ Y/Y)
Interest income on notes
receivable
$175K
(-49.28%↓ Y/Y)
Provision for credit
losses
-$73K
(-154.89%↓ Y/Y)
Income taxes
-$65K
(85.49%↑ Y/Y)
Gain on sale of assets
$32K
(-93.66%↓ Y/Y)
Buy us a coffee
Anika Therapeutics, Inc. (ANIK)
Anika Therapeutics, Inc. (ANIK)